Monkeypox Vaccine Roll-out in the U.S. – Are Jurisdictions Requesting All Their Doses? July 29, 2022 Blog This analysis examines monkeypox vaccine allocations and jurisdictional requests. It explores jurisdictional request rate (the number of vaccine does requested as a share of the jurisdiction’s allocation from HHS) for JYNNEOS, the preferred vaccine. Overall, while most jurisdictions have requested at least their full supply, some are well below that mark, raising questions about how quickly their at-risk populations can get protected.
Insulin Out-of-Pocket Costs in Medicare Part D July 28, 2022 Issue Brief Addressing the cost of insulin continues to be at the forefront of policy discussions around prescription drugs. This analysis describes out-of-pocket spending on insulin products by Medicare beneficiaries enrolled in Part D drug plans, along with state-level use and spending data.
Alice Burns July 28, 2022 Person Alice Burns is an associate director of KFF’s Program on Medicaid and the Uninsured, where she focuses on overseeing the team’s quantitative research. Prior to joining KFF in 2022, Dr. Burns served as a principal analyst at the Congressional Budget Office. She led the agency’s research using Medicaid claims data…
Update: The Number of People Not Up to Date on Vaccination in Counties with Elevated COVID-19 Community Levels is Growing July 28, 2022 Issue Brief This post provides updated estimates the number of people who are not up-to-date on COVID-19 vaccination living in counties designated by the CDC as being “high” or “medium” COVID-19 community levels. These are areas of elevated risk, with relatively high levels of new COVID-19 cases and strained hospital capacity. This analysis finds that the number of those not up to date on COVID-19 vaccination, and the most at risk for severe illness, living in areas of elevated risk has grown since early June 2022.
How Would the Prescription Drug Provisions in the Senate Reconciliation Proposal Affect Medicare Beneficiaries? July 27, 2022 Issue Brief The brief provides a quick explainer of the prescription drug provisions in legislative text released by the Senate Finance Committee to be included in a forthcoming reconciliation bill and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
Donor Governments Spent US$7.5 Billion on Efforts to Combat HIV/AIDS Globally in 2021, Largely Flat Amid the COVID-19 Pandemic, KFF-UNAID Report Finds July 27, 2022 News Release A new report from KFF (Kaiser Family Foundation) and The Joint United Nations Programme on HIV/AIDS (UNAIDS) finds that donor governments disbursed US$7.5 billion in 2021 to combat HIV in low- and middle-income countries, largely flat amid the COVID-19 pandemic and essentially matching 2008 levels, against a backdrop of growing…
Key Questions About the Current U.S. Monkeypox Outbreak July 27, 2022 Issue Brief This brief answers key questions about the U.S. monkeypox outbreak to date and identifies issues that may affect the response going forward.
43% of Parents with Children Under 5 Newly Eligible for a COVID-19 Vaccine Say They Will “Definitely Not” Get Them Vaccinated July 26, 2022 News Release Most Parents Open to Getting Their Young Child Vaccinated Haven’t Yet Spoken to Their Pediatrician Most parents of young children newly eligible for a COVID-19 vaccine are reluctant to get them vaccinated, including 43% who say they will “definitely not” do so, a new KFF COVID-19 Vaccine Monitor survey finds…
KFF COVID-19 Vaccine Monitor: July 2022 July 26, 2022 Poll Finding In the wake of the FDA’s emergency use authorization for COVID-19 vaccines for children ages 6 months through 4 years old, many parents remain hesitant to vaccinate their children in this age group, with a slight majority saying they view the vaccine as a bigger risk to their child’s health than getting infected with coronavirus.
COVID-19 Vaccination Rates Among Children Under 5 Have Peaked and Are Decreasing Just Weeks Into Their Eligibility July 22, 2022 Issue Brief Children between the ages of 6 months and 5 years of age finally became eligible for COVID-19 vaccination in the U.S. on June 18, after the Director of the Centers for Disease Control and Prevention (CDC) recommended their use for this population, following emergency use authorization granted by the Food and Drug Administration. Here, we examine the status of vaccine uptake in this group, one month into their eligibility.